Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Roland Ott who wrote (1031)	1/8/1998 4:28:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

I apologize, I meant # 828. Kind of busy watching the TCLN shakeout today. Phase I studies are only for safety and really don't amount to much since anyone can conduct one. I would wait to see if Cel-Sci can make it to P III, aren't they in a P II here? I believe they are cocktailing cytokines and injecting them as a therapeutic. There have been problems with cytokines as therapeutics, though TCLN uses tumor necrosis factor in a fusion protein. TCLN uses another cytokine, Interleukin-2, in its' VE therapy but it's utility is as a toxin. At this time Cel-Sci is not a player in the solid tumor market. There really isn't a pandemic competitor to TNT other than the traditional treatments of chemotherapy and external beam radiation. From your previous question there is no business relationship between TCLN and ENMD though the discoverers of their respective antiangiogenesis programs were colleagues at Harvard. Bristol-Myers-Squibb has a license with ENMD and is a prospective TCLN licensee, however. You might wish to take a look at the TCLN home page; techniclone.com